MA40761B1 - Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr - Google Patents
Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfrInfo
- Publication number
- MA40761B1 MA40761B1 MA40761A MA40761A MA40761B1 MA 40761 B1 MA40761 B1 MA 40761B1 MA 40761 A MA40761 A MA 40761A MA 40761 A MA40761 A MA 40761A MA 40761 B1 MA40761 B1 MA 40761B1
- Authority
- MA
- Morocco
- Prior art keywords
- fgfr
- responsive
- treatment
- cancer patients
- mutant gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Cette invention concerne des méthodes d'identification d'un patient atteint de cancer qui sera sensible au traitement avec un inhibiteur du récepteur du facteur de croissance des fibroblastes (fgfr) et des méthodes destinées à traiter des patients atteints de cancer. Les méthodes impliquent l'évaluation d'un échantillon biologique provenant du patient pour identifier la présence d'un ou de plusieurs mutants du fgfr à partir d'un panel de gènes mutants du fgfr. Des kits et des amorces pour identifier la présence d'un ou de plusieurs gènes mutants du fgfr dans un échantillon biologique sont également décrits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/050996 WO2016048833A2 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40761A MA40761A (fr) | 2017-08-01 |
| MA40761B1 true MA40761B1 (fr) | 2022-04-29 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40761A MA40761B1 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20160090633A1 (fr) |
| EP (2) | EP4063516A1 (fr) |
| JP (4) | JP6766037B2 (fr) |
| KR (3) | KR102839867B1 (fr) |
| CN (1) | CN107002141B (fr) |
| AR (1) | AR102345A1 (fr) |
| AU (3) | AU2015321626B2 (fr) |
| CA (1) | CA2962075C (fr) |
| CO (1) | CO2017003528A2 (fr) |
| CR (1) | CR20170104A (fr) |
| CY (1) | CY1125190T1 (fr) |
| DK (1) | DK3198033T3 (fr) |
| EA (1) | EA037920B1 (fr) |
| EC (1) | ECSP17025787A (fr) |
| ES (1) | ES2912567T3 (fr) |
| GT (1) | GT201700059A (fr) |
| HR (1) | HRP20220496T1 (fr) |
| HU (1) | HUE058219T2 (fr) |
| IL (3) | IL324511A (fr) |
| JO (1) | JO3681B1 (fr) |
| LT (1) | LT3198033T (fr) |
| MA (1) | MA40761B1 (fr) |
| MX (2) | MX392774B (fr) |
| MY (1) | MY194567A (fr) |
| NI (1) | NI201700035A (fr) |
| PH (1) | PH12017500556A1 (fr) |
| PL (1) | PL3198033T3 (fr) |
| PT (1) | PT3198033T (fr) |
| RS (1) | RS63178B1 (fr) |
| SG (1) | SG11201702381QA (fr) |
| SI (1) | SI3198033T1 (fr) |
| SM (1) | SMT202200177T1 (fr) |
| SV (1) | SV2017005415A (fr) |
| TW (1) | TWI706136B (fr) |
| UA (1) | UA122564C2 (fr) |
| UY (1) | UY36325A (fr) |
| WO (1) | WO2016048833A2 (fr) |
| ZA (1) | ZA201702899B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107501413A (zh) | 2012-09-27 | 2017-12-22 | 中外制药株式会社 | Fgfr3融合基因和以其作为标靶的药物 |
| JP6731254B2 (ja) * | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015144804A1 (fr) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinaisons |
| PT3198033T (pt) | 2014-09-26 | 2022-05-25 | Janssen Pharmaceutica Nv | Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr |
| TWI834020B (zh) | 2015-02-10 | 2024-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JP7085985B2 (ja) * | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP3628071B1 (fr) | 2018-07-27 | 2022-07-06 | Zepto Life Technology, LLC | Système et procédé de préparation d'échantillon dans la détection gmr de biomarqueurs |
| EA202190826A1 (ru) * | 2018-09-21 | 2021-06-16 | Янссен Фармацевтика Нв | Лечение холангиокарциномы |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| PH12021552352A1 (en) | 2019-03-29 | 2022-09-05 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| CA3130460A1 (fr) * | 2019-03-29 | 2020-10-08 | Anne Elizabeth O'HAGAN | Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothelial |
| PH12021552973A1 (en) * | 2019-05-31 | 2022-07-11 | Qed Therapeutics Inc | Methods of treating urinary system cancers |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| JPWO2021010326A1 (fr) * | 2019-07-12 | 2021-01-21 | ||
| CN115335701A (zh) * | 2019-09-09 | 2022-11-11 | 泽普托生命技术有限责任公司 | 用于检测核酸中基因变异的系统和方法 |
| KR20220070243A (ko) | 2019-09-26 | 2022-05-30 | 얀센 파마슈티카 엔.브이. | 순차적 치료 환경에서 면역 체크포인트 억제제에 대한 환자 반응을 향상시키기 위한 fgfr-유전적으로 변경된 암에서의 fgfr 억제제의 용도 |
| KR20220140781A (ko) | 2020-02-12 | 2022-10-18 | 얀센 파마슈티카 엔.브이. | 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 |
| TWI900527B (zh) | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| BR112022020846A2 (pt) * | 2020-04-15 | 2022-12-27 | Alkermes Pharma Ireland Ltd | Agentes imunoestimuladores em combinação com inibidores de angiogênese |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| JP2023542296A (ja) | 2020-09-14 | 2023-10-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｆｇｆｒ阻害剤の併用療法 |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| AU2022277796A1 (en) | 2021-05-19 | 2024-01-18 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
| EP4415692A1 (fr) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Formulations d'erdafitinib et systèmes d'administration intravésicale |
| KR20240145513A (ko) | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
| AU2024222187A1 (en) | 2023-02-13 | 2025-10-02 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| IL322667A (en) | 2023-02-13 | 2025-10-01 | Taris Biomedical Llc | Ardepitinib for intravesical administration for use in the treatment of bladder cancer |
| EP4665343A1 (fr) | 2023-02-17 | 2025-12-24 | TARIS Biomedical LLC | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie |
| WO2025059602A1 (fr) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Méthodes de traitement du cancer de la vessie à l'aide d'une administration intravésicale d'erdafitinib |
| CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| CA2372990C (fr) | 1999-05-05 | 2007-06-19 | Institut Curie | Moyens de detection et de traitement des pathologies associees au fgfr3 |
| ES2447566T3 (es) | 2002-10-01 | 2014-03-12 | Epigenomics Ag | Uso de ácidos nucleicos de PITX2 para mejorar el tratamiento de trastornos proliferativos de células mamarias |
| WO2004085676A1 (fr) * | 2003-03-26 | 2004-10-07 | Progenika Biopharma, S.A. | Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (fr) * | 2004-11-18 | 2006-05-24 | Institut Curie | Altérations des kératoses séborrhéiques et applications dérivées |
| EP2266974A1 (fr) | 2005-05-23 | 2010-12-29 | Novartis AG | Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one |
| WO2007061127A1 (fr) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Agent antitumeur pour myelomes multiples |
| JP2009523410A (ja) | 2005-12-08 | 2009-06-25 | ノバルティス アクチエンゲゼルシャフト | 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果 |
| EP1918376A1 (fr) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques |
| US20100075337A1 (en) | 2007-02-27 | 2010-03-25 | Diana Graus Porta | Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof |
| WO2008109369A2 (fr) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| WO2008157801A2 (fr) | 2007-06-21 | 2008-12-24 | Gen-Probe Incorporated | Instruments et réceptacles pour effectuer des procédés |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| WO2013173485A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de cancers de la vessie |
| WO2013173480A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de récurrence de cancer de la vessie |
| GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| CN102448984A (zh) | 2009-03-27 | 2012-05-09 | 酶遗传学股份有限公司 | 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法 |
| WO2011027219A1 (fr) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | Détection à rendement élevé de petites délétions et insertions génomiques |
| WO2011115937A1 (fr) * | 2010-03-14 | 2011-09-22 | The Translational Genomics Research Institute | Procédés de détermination de la sensibilité de tumeurs à des inhibiteurs de la tyrosine kinase |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| WO2013026027A1 (fr) | 2011-08-18 | 2013-02-21 | Nestec S.A. | Compositions et procédés pour la détection de variants alléliques |
| EP2761300A4 (fr) * | 2011-09-27 | 2015-12-02 | Univ Michigan | Fusions de gènes récurrentes dans le cancer du sein |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (fr) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3 |
| PT2824181T (pt) | 2012-03-08 | 2018-12-20 | Astellas Pharma Inc | Novo produto de fusão de fgfr3 |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| CN104619840A (zh) * | 2012-07-05 | 2015-05-13 | 日本国立癌症研究中心 | Fgfr2融合基因 |
| CN104797936B (zh) * | 2012-07-24 | 2017-11-24 | 纽约市哥伦比亚大学理事会 | 融合蛋白及其方法 |
| RU2015102194A (ru) * | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
| CN107501413A (zh) | 2012-09-27 | 2017-12-22 | 中外制药株式会社 | Fgfr3融合基因和以其作为标靶的药物 |
| ES2949394T3 (es) * | 2012-11-05 | 2023-09-28 | Found Medicine Inc | Moléculas de fusión novedosas y usos de las mismas |
| CA3150658A1 (en) * | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| EP2981621B1 (fr) | 2013-04-05 | 2019-05-22 | Life Technologies Corporation | Fusions géniques |
| WO2014193229A2 (fr) | 2013-05-27 | 2014-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Nouvelles translocations dans le cancer du poumon |
| WO2015006723A1 (fr) | 2013-07-12 | 2015-01-15 | The Regents Of The University Of Michigan | Fusions de gènes récurrentes dans le cancer |
| PT3198033T (pt) | 2014-09-26 | 2022-05-25 | Janssen Pharmaceutica Nv | Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr |
| US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| BR112019016043A2 (pt) | 2017-02-06 | 2020-03-31 | Janssen Pharmaceutica Nv | Tratamento de câncer |
-
2015
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/fr not_active Ceased
- 2015-09-18 CA CA2962075A patent/CA2962075C/fr active Active
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 IL IL324511A patent/IL324511A/en unknown
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/fr active Pending
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 KR KR1020227040649A patent/KR102839867B1/ko active Active
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/fr active Active
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 KR KR1020257024958A patent/KR20250119657A/ko active Pending
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-23 IL IL291633A patent/IL291633B1/en unknown
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40761B1 (fr) | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| WO2008088854A3 (fr) | Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie | |
| MX2022014633A (es) | Metodos para detectar norovirus. | |
| AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
| EA200971079A1 (ru) | ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ | |
| DK2114990T3 (da) | Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor | |
| MY204203A (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| MX2025004102A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| WO2016146254A8 (fr) | Agents destinés à être utilisés dans le traitement thérapeutique ou prophylactique de la myopie ou de l'hypermétropie | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| WO2008147206A3 (fr) | Moyens et procédés permettant de classer des échantillons de patients atteints de sclérose en plaques | |
| EP3935190A4 (fr) | Réactifs, procédés et kits pour identifier des femmes enceintes à risque de trouble(s) du lit placentaire | |
| FR3055339B1 (fr) | Methode de detection et d'identification in vitro d'un ou plusieurs pathogenes cibles presents dans un echantillon biologique | |
| WO2020123880A3 (fr) | Réarrangements génomiques associées à un cancer de la prostate, et leurs procédés d'utilisation | |
| EA201992112A1 (ru) | Способы лечения опухоли | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| ATE530668T1 (de) | Verfahren und kits zur brustkrebsprognose | |
| Kissell et al. | Enhancing Ministry & Improving Clergy Well-Being: Exploring the impact of Bowen’s Systems Coaching on the Work-Related Psychological Health of Clergy | |
| ES2640524A1 (es) | Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas | |
| JOP20210052A1 (ar) | علاج سرطان الأوعية الصفراوية | |
| Cantu et al. | P116 Complement component 1q assay lacks sensitivity and trends with de novo donor-specific antibody titers | |
| Chakraborty et al. | A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents | |
| Hnatyshyn | The Key Factors Of Gaining Professional Skills | |
| NZ761242A (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |